Acción 0VY I-MAB
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas I-Mab Deutsche Boerse AG

Acciones

0VY

US44975P1030

Tiempo real estimado Tradegate
Otros sitios de cotización
 20:58:31 27/06/2024 		Varia. Cinco días. Varia. 1 de enero.
1,555 EUR -2,20 % Gráfico intradía de I-Mab -1,26 % -4,85 %
06/06 I-Mab nombra a Phillip Dennis director médico CI
05/06 I-Mab colabora con Bristol-Myers para evaluar Givastomig en un estudio combinado para cánceres gástricos y esofágicos MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab Appoints Phillip Dennis as Chief Medical Officer
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
I-Mab to Participate at the Jefferies Global Healthcare Conference
I-MAB Filed 2023 Annual Report on Form 20-F
Verastem Names John Hayslip as Chief Medical Officer
I-Mab Announces Chief Medical Officer Changes
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
I-Mab Completes Business Divestiture in China
I-Mab Announces Closing of the Divestiture of Business Operations in China
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.
I Mab : Resignations of Director and Senior Management - Form 6-K
I-Mab Announces Executive Resignation
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
I-Mab Divests China Operations, Shifts Focus to US Market
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción IMAB
  4. Acción 0VY
  5. Noticias I-Mab
  6. Otros idiomas